Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Psychiatry
Volume 2017, Article ID 5064047, 3 pages
https://doi.org/10.1155/2017/5064047
Case Report

Treatment of Hypochondriasis in Two Schizophrenia Patients Using Clozapine

Istituto di Psicopatologia, Via Girolamo da Carpi 1, 00196 Rome, Italy

Correspondence should be addressed to Antonio Tundo; ti.aigolotapocispidotutitsi@odnut

Received 14 February 2017; Revised 24 April 2017; Accepted 2 May 2017; Published 31 May 2017

Academic Editor: Douglas L. Noordsy

Copyright © 2017 Antonio Tundo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Swets, J. Dekker, K. van Emmerik-van Oortmerssen et al., “The obsessive compulsive spectrum in schizophrenia, a meta-analysis and meta-regression exploring prevalence rates,” Schizophrenia Research, vol. 152, no. 2-3, pp. 458–468, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. N. A. Fineberg, M. P. Hengartner, C. E. Bergbaum et al., “A prospective population-based cohort study of the prevalence, incidence and impact of obsessive-compulsive symptomatology,” International Journal of Psychiatry in Clinical Practice, vol. 17, no. 3, pp. 170–178, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. F. Schirmbeck and M. Zink, “Effect of antipsychotic treatment on obsessive-compulsive symptoms,” in Obsessive-Compulsive Symptoms in Schizophrenia, L. De Haan, F. Schirmbeck, and M. Zink, Eds., pp. 147–175, Springer International Publishing, Basel, Switzerland, 2015. View at Google Scholar
  4. G. Grassi, L. Poli, A. Cantisani, L. Righi, G. Ferrari, and S. Pallanti, “Hypochondriasis and obsessive-compulsive disorder in schizophrenic patients treated with clozapine vs other atypical antipsychotics,” CNS Spectrums, vol. 19, no. 4, pp. 340–346, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. O. J. Bienvenu, J. F. Samuels, L. A. Wuyek et al., “Is obsessive–compulsive disorder an anxiety disorder, and what, if any, are spectrum conditions? A family study perspective,” Psychological Medicine, vol. 42, no. 1, pp. 1–13, 2012. View at Publisher · View at Google Scholar
  6. American Psychiatric Association, “Practice guideline for the treatment of patients with obsessive-compulsive disorder,” The American Journal of Psychiatry, vol. 1, pp. 164–56, 2007. View at Google Scholar
  7. S. Englisch and M. Zink, “Polypharmacy for obsessive compulsive symptoms in schizophrenia: augmentation and combination strategies,” in Obsessive compulsive symptoms in schizophrenia, L. De Haan, F. Schirmbeck, and M. Zink, Eds., pp. 179–202, Springer International Publishing, Basel, Switzerland, 2015. View at Publisher · View at Google Scholar
  8. A. Tundo and R. Necci, “Cognitive-behavioural therapy for obsessive-compulsive disorder co-occurring with psychosis: Systematic review of evidence,” World Journal of Psychiatry, vol. 6, no. 4, pp. 449–455, 2016. View at Publisher · View at Google Scholar
  9. S. Lin, S. Su, and C. Pan, “Higher plasma drug concentration in clozapine-treated schizophrenic patients with side effects of obsessive/compulsive symptoms,” Therapeutic Drug Monitoring, vol. 28, no. 3, pp. 303–307, 2006. View at Publisher · View at Google Scholar
  10. S. R. Kay, A. Fiszbein, and L. A. Opler, “The positive and negative syndrome scale (PANSS) for schizophrenia,” Schizophrenia Bulletin, vol. 13, no. 2, pp. 261–276, 1987. View at Publisher · View at Google Scholar · View at Scopus
  11. W. Guy, “Clinical global impressions (028-CGI),” in ECDEU Assessment Manual for Psychopharmacology Revised, U.S. Department of Health, Education, and Welfare Publication (ADM), Psychopharmacology Research Branch, pp. 218–222, National Institute of Mental Health, Rockville, Md, USA, 1976. View at Google Scholar
  12. S. H. Jones, G. Thornicroft, M. Coffey, and G. Dunn, “A brief mental health outcome scale. Reliability and validity of the global assessment of functioning (GAF),” British Journal of Psychiatry, vol. 166, pp. 654–659, 1995. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Greeven, P. Spinhoven, and A. J. L. M. Van Balkom, “Hypochondriasis Y-BOCS: A study of the psychometric properties of a clinician-administered semi-structured interview to assess hypochondriacal thoughts and behaviours,” Clinical Psychology and Psychotherapy, vol. 16, no. 5, pp. 431–443, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Zink, “Comorbid obsessive-compulsive symptoms in schizophrenia: insight into pathomechanisms facilitates treatment,” Advances in Medicine, Article ID 317980, 18 pages, 2014. View at Publisher · View at Google Scholar
  15. C. Asenjo Lobos, K. Komossa, C. Rummel-Kluge et al., “Clozapine versus other atypical antipsychotics for schizophrenia,” Cochrane Database of Systematic Reviews, vol. 11, article CD006633, 2010. View at Google Scholar · View at Scopus
  16. J. P. McEvoy, J. A. Lieberman, T. S. Stroup et al., “Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment,” The American Journal of Psychiatry, vol. 163, no. 4, pp. 600–610, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Tiihonen, J. Lönnqvist, K. Wahlbeck et al., “11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study),” The Lancet, vol. 374, no. 9690, pp. 620–627, 2009. View at Publisher · View at Google Scholar · View at Scopus